Coordinatore | UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
Nazionalità Coordinatore | Italy [IT] |
Totale costo | 100˙000 € |
EC contributo | 100˙000 € |
Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
Code Call | FP7-PEOPLE-2007-4-3-IRG |
Funding Scheme | MC-IRG |
Anno di inizio | 2008 |
Periodo (anno-mese-giorno) | 2008-09-03 - 2012-09-02 |
# | ||||
---|---|---|---|---|
1 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | coordinator | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'SMYD3 is a histone methylase that di- and tri-methylates histone H3 at lysine 4. In normal conditions SMYD3 is highly expressed only in skeletal muscle and testis. We hypothesize that SMYD3 plays an important role in transcriptional regulation throughout myogenesis. We will use C2C12 myoblast and primary satellite cells as model systems to assess the contribution of SMYD3 to the transcriptional regulation of muscle specific genes. We will over-express and knock down SMYD3 to determine the impact of SMYD3 on the expression of myogenic markers and the ability of C2C12 cells to fuse into multinucleated myotubes. We will also determine functional mechanisms that account for a potential involvement of SMYD3 in myogenesis by employing chromatin immunoprecipitation experiments. Moreover, we will identify SMYD3 target genes in muscle cells by RNA microarray analysis and by the combination of the chromatin immunoprecipitation technique with massively sequencing technology (ChIp-seq). A further objective of the project will be to gain insights into the mechanisms underlying SMYD3 activity and its modulation, by exploiting in vitro and in vivo approaches.'
Development of a strategy to treat limb-girdle muscular dystrophy (LGMD2A) using combined cell and gene therapy strategies
Read More